Genetic study to find new treatments for leukemia after MPN
Part of Blood & lymphatic clinical trials.
This study is looking at the genetic changes that happen when a myeloproliferative neoplasm (a type of blood cancer) turns into acute myeloid leukemia. It aims to find new treatments that target these specific changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been told you have a myeloproliferative neoplasm (MPN), such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
- Your MPN has transformed into acute myeloid leukemia (AML), meaning you have at least 20% blast cells in your blood or bone marrow.
- A bone marrow sample was taken after this transformation and has enough material (like DNA, RNA, or frozen cells) for research.
- You agree to participate by signing an informed consent form.
- You must be covered by the French health insurance system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This study uses advanced tests (genetics and other 'omics' methods) to better understand your leukemia and find a treatment that targets its specific features. It may help if standard treatments haven't worked or stopped working.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This study explores whether certain inherited gene changes make people more likely to develop myeloproliferative neoplasms (MPNs). It is looking at patients who were diagnosed at a young age or have a family history of blood cancers, to better understand the genetic causes of these conditions.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.